title: Requirement of endogenous basic fibroblast growth factor for sensitization to amphetamine.
abstract: Repeated exposure to amphetamine produces long-lasting increases in sensitivity to its effects. We reported previously that repeated amphetamine treatment results in increased astrocytic expression of basic fibroblast growth factor (bFGF) in the ventral tegmental area (VTA) and substantia nigra compacta (SNc) and that this effect is prevented by coadministration of a nonspecific glutamate receptor antagonist. Here we show that the development of sensitization to amphetamine is prevented when amphetamine injections are preceded by infusions of a neutralizing antibody to bFGF into the VTA. In addition, we show that astrocytic bFGF expression is increased in the VTA and SNc of animals that exhibit behavioral sensitization and that the number of bFGF-immunoreactive astrocytes in these regions is strongly and positively correlated with the magnitude of sensitization. Cotreatment with an NMDA glutamate receptor antagonist blocks both the development of behavioral sensitization and bFGF induction. These results show that endogenous bFGF is necessary for the development of sensitization to amphetamine and suggest that bFGF mediates the glutamatergic-dopaminergic interaction that initiates the long-term consequences of repeated drug use.
authors.affiliation: Center for Studies in Behavioral Neurobiology Department of Psychology, Concordia University, Montreal, Quebec H3G 1M8, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Flores
authors.forename: A N
authors.initials: AN
authors.lastname: Samaha
authors.forename: J
authors.initials: J
authors.lastname: Stewart
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001253:Astrocytes / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects*; D001667:Binding, Competitive; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000276:immunology / Q000378:metabolism*; D018698:Glutamic Acid / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013239:Stereotyped Behavior / Q000187:drug effects; D017557:Ventral Tegmental Area / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000697:Central Nervous System Stimulants; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; D016222:Fibroblast Growth Factor 2; C104291:3-(2-carboxypiperazine-4-yl)propyl-1-phosphate; D018698:Glutamic Acid; D000661:Amphetamine